Browse Research Interests

Ageing
Allergy
Bioethics
Biomedical Engineering
Biostatistics
Cancer
	Dr Tobias Arkenau     Prince of Wales Clinical School Statement of Interests: In the field of cancer medicine the development of new anti-cancer agents is of special interest, with a special focus on the treatment of gastro-intestinal cancers. Additionally, clinical trial design and biomarker development. More...
	Professor Philip Crowe     Prince of Wales Clinical School - Department of Surgery Statement of Interests: Broad interest in treatment of soft tissue sarcoma, particularly trialing new treatment regimens. Lab based research is focused on identifying markers of prognosis and potential targets for new therapies. Clinical research in endocrine and cancer surgery. More...
	Dr Timothy Dobbins     Prince of Wales Clinical School Statement of Interests: Enjoys applying statistical methods to guide research in health and medicine. The design and analysis of cluster randomsied trials is a particular research interest. More...
	Dr Margaret Faedo     Prince of Wales Clinical School Statement of Interests: One of the biggest challenges facing health care systems today is providing patients with access to new and emerging drug treatments, and at the same time ensuring the sustainability of funding. Local health care delivery systems, such as area health services, hospitals and private health insurers are under considerable pressure to fund medicines rejected, restricted or pending approval by the Pharmaceutical Benefits Advisory Committee. There is a need to develop freely available economic models that can adapt easily to local circumstances. This requires new policies and health care practices developed on the basis of sound clinical and economic evidence. Our NHMRC funded program aims to build and disseminate readily accessible evidence about the cost effectiveness of cancer medicines in clinical practice. These models will be available on the Cancer Institute NSW Standard Treatment (CI-SCaT) program, an online resource of more than 500 peer-reviewed cancer treatment guidelines. This is a world first program which will have implications beyond cancer management, addressing one of the most enduring problems in health care: the translation of economic evidence into policy and clinical practice. More...
	Dr Luke Hesson     Prince of Wales Clinical School Statement of Interests: Research within the Molecular and Cellular Oncology Laboratory aims to investigate the genetic and epigenetic basis of colon cancer. More...
	Dr Sian Hicks     Prince of Wales Clinical School Statement of Interests: Colorectal cancer is currently the most common cancer diagnosed in Australia and has the second highest incidence of cancer-related deaths. Our research group, the Colorectal Cancer Research Consortium, was established to develop and test better systems for the identification, integration and dissemination of clinically relevant information about colorectal cancers and to use this information as a basis to develop research that could be translated into clinical practice. Current project include: - Development of synoptic pathology reporting for colorectal cancer - Identification of data that is essential for the reporting of colorectal cancer by the Clincial Cancer Registry - Integration of mismatch repair deficiency testing (MMRD)into pathology reporting of colorectal cancer - Microsatellite instability in colorectal cancer as a prognostic indicator for metachronous cancers More...
	Dr Megan Hitchins     Prince of Wales Clinical School Statement of Interests: Research focus is the role of genetic and epigenetic changes in disease development including both congenital disorders and cancer, and the inheritance patterns associated with these molecular abnormalities. This has included research into the aetiological role of genomic imprinting during fetal development, and more recently, germline epimutations in hereditary cancers. The patterns of somatic epigenetic changes in the development of sporadic cancer, and the underlying mechanisms are also of interest. More...
	Dr Tzong-Tyng Hung     Prince of Wales Clinical School Statement of Interests: Secondary bone lesions (bone metastasis) is a major cause of mortality and morbidity in prostate cancer. The mechanisms of bone metastasis is still unclear. In order to study bone metastasis, we have developed murine models that are bone metastatic. Using various imaging and detection systems (microCT scans for small animals, Bioluminescence imaging, Fluorescent imaging and ultrasound) we are able to monitor development of bone metastatic lesions and pinpoint the site of bone tumours. Importantly, our models involve immune competent mice, which allows us to investigate the role of immune cells on the development of secondary bone tumours in prostate cancer and also evaluate potential therapies which include immunotherapies. More...
	Dr Aparajita Khatri     Prince of Wales Clinical School Statement of Interests: Cancer imaging and therapeutics; Specifically, targeted combination therapies involving novel combinations e.g gene therapy and traditional therapy (Collaborations with Prof david T curiel (Alabama,USA) & Dr. Leif Lindholm(Sweden). Biomedical applications of magnetic nanoparticles for cancer imaging and therapy (Collaboration with Dr Benjamin Thierry, South Australia) More...
	Dr Craig Lewis     Prince of Wales Clinical School - Department of Medicine Statement of Interests: Major areas of clinical trial research in breast, lung and genitourinary cancer. Other areas of interest include cancer pain management and chemotherapy-related nausea and vomiting More...
	Dr Limin Mao     Prince of Wales Clinical School Statement of Interests: Cancer epidemiology, HIV/AIDS and its risky behaviors, and primary health care are of particular interest. More...
	Associate Professor Bettina Meiser     Prince of Wales Clinical School Statement of Interests: An ongoing research program that incorporates both qualitative and quantitative research methodologies focuses on the psychological impact of genetic testing and counselling for adult-onset disorders, in particular cancer susceptibility; psychological adjustment of those at risk for adult-onset disorders; the design and evaluation of interventions in the genetic counselling setting, in particular decision aids as an innovative means of patient education; and the impact of prophylactic surgery in individuals at high risk for cancer. Another area of research is cultural aspects of cancer genetics. More...
	Dr Sallie-Anne Pearson     Prince of Wales Clinical School Statement of Interests: Sallie is a health service researcher specialising in clinician behaviour change, pharmacoepidemiology and pharmaceutical policy evaluation. She has conducted this research in Australia, the United States and the developing world. Sallie completed her doctoral training in 1998 at the University of Newcastle, Australia and was the inaugural Postdoctoral Fellow in Pharmaceutical Policy at Harvard Medical School from 2000-2001. She returned to Australia in 2002 where she worked as a consultant to the WHO Collaborating Centre in Pharmaceutical Policy Boston and Medicare Australia for two years. She returned to academia in 2004 and in March 2006 joined the Integrated Cancer Research Group as the Pharmacoepidemiology and Pharmaceutical Policy Team Leader. She is currently a Cancer Institute NSW Health Services Research Fellow (2006-2009). Sallie's current research interests focus on three core areas: 1. Using secondary data sources to investigate the use and impact of medicines in real world clinical prcatice 2. Clinician behaviour change, specifically the use and uptake of electronic decision support to guide prescribing practice 3. Investigating the direct and indirect costs of cancer care from the perspective of health care payers and patients More...
	Dr John Pimanda     Prince of Wales Clinical School Statement of Interests: Haematopoietic Stem Cells (HSCs) represent the best characterized adult multipotent stem cell population. Transcriptional regulation is a key mechanism controlling the formation and subsequent behaviour of HSCs. To investigate gene regulatory networks that operate during HSC specification, we use computational tools to predict regulatory elements of key haematopoietic transcription factor genes. We then filter these predictions using array based chromatin accessibility and transcription factor binding profiles. Transgenic mice are generated to test whether these predicted elements show tissue specific activity in the developing embryo. We also investigate mesenchymal stem/progenitor cell (MSCs)development to compare and contrast gene transcription between HSCs and MSCs. Knowledge of the normal transcriptional hierarchies of these cell types can be applied to better understand the dysregulation of these networks in the pathogenesis of cancer. To this end, we also study the biology of blood stem cell dyscrasias with a particular focus on the myelodysplastic and myeloproliferative syndromes. More...
	Dr Carl A Power     Prince of Wales Clinical School Statement of Interests: In the area of cancer biology in general and specifically prostate cancer biology. Research is focused on use of animal models to identify mechanisms of prostate cancer metastasis to bone, immune responses to prostate cancer and its bone metastases and preclinical assessment of treatments to prevent bone mets. More...
	Professor Pam Russell     Prince of Wales Clinical School - Department of Medicine Statement of Interests: The Oncology Research Centre has been working since 1992 on preclinical studies of cancer, mostly prostate and bladder cancer, but also other cancers, including ovarian, colon and sarcoma. There are four main research areas: molecular studies of how cancers progress; gene therapy (suicide and immunological genes) for advanced prostate cancer, studies of the biology of and treatment for tumours that spread to the bone, and studies using targeted nanoparticles to improve cancer imaging. Approaches include the use of conditionally replicative adenoviruses with both transcriptional control and surface modulation of the virus to target cancer cells and deliver genes into tumours, animal models, including the growth of human tumours in the tibia of immunosuppressed mice or after intracardiac injection, that allows spontaneous spread to other organs, and microarray to identify genes of importance in the invasive/metastatic process. In addition, we are involved in the development of an animal imaging facility that is closely aligned to a specific pathogen free facility for rodents, so that preclinical studies can be appropriately performed in a longitudinal fashion, following through individual mice over time. More...
	Dr Robert Smee     Prince of Wales Clinical School Statement of Interests: The practice of Medicine requires an evidence based approach with clinical audit to determine comparable results to peers. Thus clinical research both retrospective and prospective, is practised in the field of Neuro-Oncology and Head & Neck Cancers. Developing new methods of treatment via Stereotactic Radiotherapy is important. Psychological distress amongst brain tumour patients is also evaluated. More...
	Ms Preeyaporn Srasuebkul     Prince of Wales Clinical School Statement of Interests: -- More...
	Professor Robyn Ward     Prince of Wales Clinical School Statement of Interests: In the field of hereditary cancer, the impact of germline epimutations as a cause of cancer is a main field of study. This work represents a substantive change in our understanding of colorectal cancer predisposition, and is of clinical relevance. In the clinical field research studies involve interventional and observational studies of targeted therapies for cancer. In health policy, the research activities revolve around developing cost effective models for the use of cancer medicines in our community. More...
	Dr Yan Yu     Prince of Wales Clinical School - Department of Surgery Statement of Interests: Dr Yan Yu is currently a Principal Hospital Scientist of Prince of Wales Hospital and the Section Head of Orthopaedic Pathology & Molecular Biology of the Surgical & Orthopaedic Research Laboratories. She is also a conjoint senior lecturer of the Faculty of Medicine, University of New South Wales. She obtained a PhD degree for her work on allergy and immunology from the University of Bern in Switzerland in 1992. She is one of the pioneers in the establishment of the Surgical & Orthopaedic Research Laboratories. Her research specialties range from animal surgery to tissue pathology, cell biology, protein analysis and molecular biology. Her research interests includes skeletal responses to injuries and/or implantations; osteoporosis and osteoporotic bone defect healing; osteogenesis and tumourigenesis of human osteosarcoma cell lines; mechanisms of osteosarcoma local growth and distance metastasis and targeted therapies; tendon healing; amongst others. More...
Cardiology and Vascular Disease
Cell Biology and Gene Regulation
Clinical Governance
Clinical Research
Diabetes
Epidemiology
Evidence Based Medicine
Gastrointestinal Diseases
Genetics - Genome Analysis
Gerontology - Geriatrics
Global Health
Haematology
Health Policy
Health Services Research
HIV - AIDS
Imaging / Radiology
Immunology
Infectious Diseases
Inflammation
Injury
Medical Education
Medical Informatics
Metabolism
Molecular Structure & Drug Design
Neurodegenerative Diseases
Neurology
Neuroscience
Ophthalmology
Orthopaedics
Pain
Pathology
Pharmacology
Physiology
Population Health
Preventive Medicine
Primary Health Care
Pulmonary Disease
Rehabilitation
Renal Disease
Stem Cells
Surgery
Toxicology
Transplantation
Virology